User login
Key clinical point: Calcium pyrophosphate deposition disease (CPPD) and chondrocalcinosis are more prevalent in seronegative vs seropositive rheumatoid arthritis (RA), and the symmetry of arthritis and the acuteness of attack best differentiate CPDD and RA.
Major finding: CPPD (84.9% vs 15.1%) and chondrocalcinosis (32.3% vs 16.6%; P < .001) were more prevalent in seronegative vs seropositive RA, with acute attacks being more frequent in CPDD (67.9%) than seronegative (28.2%) or seropositive (25.9%; P < .001) RA and symmetric arthritis being more prevalent in RA than CPDD (P = .007).
Study details: This was a retrospective cross-sectional study including 503 patients, of which 262 had RA (142 seropositive, 120 seronegative), 181 had CPPD, 30 had gout, and 30 had polymyalgia rheumatica.
Disclosures: This study did not declare any specific source of funding. No competing interests were declared.
Source: Krekeler M et al. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022;8:e002383 (Jun 14). Doi: 10.1136/rmdopen-2022-002383
Key clinical point: Calcium pyrophosphate deposition disease (CPPD) and chondrocalcinosis are more prevalent in seronegative vs seropositive rheumatoid arthritis (RA), and the symmetry of arthritis and the acuteness of attack best differentiate CPDD and RA.
Major finding: CPPD (84.9% vs 15.1%) and chondrocalcinosis (32.3% vs 16.6%; P < .001) were more prevalent in seronegative vs seropositive RA, with acute attacks being more frequent in CPDD (67.9%) than seronegative (28.2%) or seropositive (25.9%; P < .001) RA and symmetric arthritis being more prevalent in RA than CPDD (P = .007).
Study details: This was a retrospective cross-sectional study including 503 patients, of which 262 had RA (142 seropositive, 120 seronegative), 181 had CPPD, 30 had gout, and 30 had polymyalgia rheumatica.
Disclosures: This study did not declare any specific source of funding. No competing interests were declared.
Source: Krekeler M et al. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022;8:e002383 (Jun 14). Doi: 10.1136/rmdopen-2022-002383
Key clinical point: Calcium pyrophosphate deposition disease (CPPD) and chondrocalcinosis are more prevalent in seronegative vs seropositive rheumatoid arthritis (RA), and the symmetry of arthritis and the acuteness of attack best differentiate CPDD and RA.
Major finding: CPPD (84.9% vs 15.1%) and chondrocalcinosis (32.3% vs 16.6%; P < .001) were more prevalent in seronegative vs seropositive RA, with acute attacks being more frequent in CPDD (67.9%) than seronegative (28.2%) or seropositive (25.9%; P < .001) RA and symmetric arthritis being more prevalent in RA than CPDD (P = .007).
Study details: This was a retrospective cross-sectional study including 503 patients, of which 262 had RA (142 seropositive, 120 seronegative), 181 had CPPD, 30 had gout, and 30 had polymyalgia rheumatica.
Disclosures: This study did not declare any specific source of funding. No competing interests were declared.
Source: Krekeler M et al. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022;8:e002383 (Jun 14). Doi: 10.1136/rmdopen-2022-002383